Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

被引：0
|
作者：
Heisen, M.
Treur, M. J.
van der Hel, W. S.
Groot, M. T.
Verheggen, B. G.
机构：
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Novartis Pharma BV, Arnhem, Netherlands
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [32] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
    Roos, I.
    Sharmin, S.
    Ozakbas, S.
    Horakova, D.
    Havrdova, E. K.
    Boz, C.
    Alroughani, R.
    Patti, F.
    Terzi, M.
    Lechner-Scott, J.
    Izquierdo, G.
    Eichau, S.
    Grammond, P.
    Buzzard, K.
    Skibina, O.
    Prat, A.
    Girard, M.
    Duquette, P.
    Soysal, A.
    Grand'Maison, F.
    Kuhle, J.
    van der Walt, A.
    Butzkueven, H.
    Turkoglu, R.
    Butler, E.
    Laureys, G.
    van Hijfte, L.
    Shaygannejad, V.
    Yamout, B.
    Khoury, S.
    Prevost, J.
    Sidhom, Y.
    Gouider, R.
    Cartechini, E.
    Sanchez-Menoyo, J. L.
    Sa, M. Jose
    Macdonell, R.
    van Pesch, V.
    Ramo-Tello, C.
    McCombe, P.
    Willekens, B.
    Spitaleri, D.
    Ampapa, R.
    Al-Asmi, A.
    Slee, M.
    Besora, S.
    Malpas, C.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
  • [33] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis
    Grahl, S.
    Bussas, M.
    Wiestler, B.
    Eichinger, P.
    Gaser, C.
    Kirschke, J.
    Zimmer, C.
    Berthele, A.
    Hemmer, B.
    Muehlau, M.
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2589 - 2597
  • [34] The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis
    Kotov, S. V.
    Fedorova, S. I.
    Yakushina, T. I.
    Lizhdvoy, V. Yu
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 74 - 78
  • [35] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [36] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [37] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
  • [38] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [39] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
    Sharmin, S.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Skibina, O.
    Buzzard, K.
    van der Walt, A.
    Vucic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 8 - 9
  • [40] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
    Sharmin, Sifat
    Lefort, Mathilde
    Andersen, Johanna Balslev
    Leray, Emmanuelle
    Horakova, Dana
    Havrdova, Eva Kubala
    Alroughani, Raed
    Izquierdo, Guillermo
    Ozakbas, Serkan
    Patti, Francesco
    Onofrj, Marco
    Lugaresi, Alessandra
    Terzi, Murat
    Grammond, Pierre
    Grand'Maison, Francois
    Yamout, Bassem
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Boz, Cavit
    Trojano, Maria
    McCombe, Pamela
    Slee, Mark
    Lechner-Scott, Jeannette
    Turkoglu, Recai
    Sola, Patrizia
    Ferraro, Diana
    Granella, Franco
    Prevost, Julie
    Maimone, Davide
    Skibina, Olga
    Buzzard, Katherine
    Van der Walt, Anneke
    Van Wijmeersch, Bart
    Csepany, Tunde
    Spitaleri, Daniele
    Vucic, Steve
    Casey, Romain
    Debouverie, Marc
    Edan, Gilles
    Ciron, Jonathan
    Ruet, Aurelie
    De Seze, Jerome
    Maillart, Elisabeth
    Zephir, Helene
    Labauge, Pierre
    Defer, Gilles
    Lebrun-Frenay, Christine
    Moreau, Thibault
    Berger, Eric
    CNS DRUGS, 2021, 35 (11) : 1217 - 1232
12345